Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Rigel Pharmaceuticals (NASDAQ: RIGL) has announced the granting of inducement awards to new employees under NASDAQ Listing Rule 5635(c)(4). The company granted a total of 23,075 stock options and restricted stock units to 10 non-executive employees. These equity awards will vest over a four-year period with a one-year cliff.

Rigel, founded in 1996 and based in South San Francisco, is a biotechnology company focused on developing therapies for hematologic disorders and cancer.

News Market Reaction

-0.48%

1 alert

-0.48% News Effect

On the day this news was published, RIGL declined 0.48%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., July 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 23,075 stock options and restricted stock units to 10 non-executive employees vesting over four years with a one-year cliff.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, its marketed products and pipeline of potential products, please visit www.rigel.com.

Contact for Investors & Media
Rigel Pharmaceuticals, Inc. 
650.624.1232
ir@rigel.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302498479.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

What inducement grants did Rigel Pharmaceuticals (RIGL) announce in July 2025?

Rigel announced granting 23,075 stock options and restricted stock units to 10 non-executive employees, with vesting over four years and a one-year cliff.

How many employees received inducement grants from Rigel (RIGL) in July 2025?

10 non-executive employees received inducement grants from Rigel Pharmaceuticals.

What is the vesting schedule for Rigel's (RIGL) July 2025 inducement grants?

The inducement grants vest over a four-year period with a one-year cliff.

What is Rigel Pharmaceuticals' (RIGL) main business focus?

Rigel is a biotechnology company focused on discovering, developing and providing novel therapies for hematologic disorders and cancer.